GMM Pfaudler Limited — Q3 FY25 earnings call

Call held 6 Feb 2025

Management summary

GMM Pfaudler reported a stable Q3 FY25 revenue of INR 801 crores, with EBITDA up 3% QoQ and margins improving to 12%. Order intake remained strong at INR 798 crore, contributing to a 7% increase in backlog to INR 1740 crore. Management highlighted progress in cost rationalization, manufacturing footprint optimization, and diversification away from cyclical chemical and pharma sectors, targeting a 15% margin profile and reduced segment exposure in the medium term, despite a cautious outlook on market recovery.

Highlights

  • Revenue for Q3 FY25 was stable at approximately INR 801 crores.

  • EBITDA for Q3 FY25 increased by 3% compared to the previous quarter.

  • EBITDA margins improved slightly to 12% in Q3 FY25, up from 11.6% in the previous quarter.

  • Q3 FY25 order intake was strong at INR 798 crore, representing a 5% increase compared to the previous quarter.

  • On a nine-month basis, order intake grew by 13% compared to the previous nine months.

  • Order backlog stands at INR 1740 crore, a 7% increase compared to December 31st, 2023.

  • The company aims for a 15% margin profile across its businesses in the medium term.

  • Exposure to chemical and pharma segments is targeted to reduce to 50% over the next couple of years.

Key financials

3 periods

Headline

  • Revenue
    ₹801 Cr
    QoQ 0%
  • EBITDA Growth
    3%
    QoQ +3%
  • EBITDA Margin
    12%
    QoQ +3.5%
  • Order Backlog
    ₹1,740 Cr
    YoY +7%

Q3

  • Order Intake
    ₹798 Cr
    QoQ +5%

9M

  • Order Intake Growth
    13%
    YoY +13%

What they filed

Q1 FY27: revenue up 16.4%, net profit up 120.0% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue805 801 807 795 902 +12%884 +10%944 +17%925 +16%
EBITDA93 96 83 101 122 +31%105 +9%75 −10%94 −7%
Net profit15 40 -28 10 39 +160%-11 −127%15 +154%22 +120%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Guidance & targets

Profitability

  • EBITDA Margin Profile Profitability · medium term · Medium confidence 15%
    So it fluctuates, but I would say as a group, our aim is to have a 15% margin profile across the businesses that we operate.

    — Tarak Patel

  • Overall EBITDA Margins Profitability · next financial year · Medium confidence Improvement
    We do want to improve margins for the next financial year

    — Tarak Patel

Market Exposure

  • Chemical and Pharma Revenue Contribution Market Exposure · next couple of years · Medium confidence 50%
    our exposure to these segments is reducing, and I would say maybe the next couple of years, it would be down to 50%

    — Tarak Patel

Business Growth

  • Heavy Engineering Business Growth Business Growth · next two, three years at least · Medium confidence big growth driver
    So heavy engineering will continue to be a focus area for us, and a big growth driver in the next two, three years at least.

    — Aseem Joshi

Strategic Vision

  • Articulation of Long-Term Vision Strategic Vision · next financial year · Medium confidence Articulate vision
    in the next financial year we should definitely be able to articulate our vision to the outside world.

    — Tarak Patel

Risks & concerns

  • Slowdown in Chemical Industry (especially agrochemicals)

    medium

    The chemical industry, which forms a major part of our order intake, is a bit slow, mainly driven by the slowdown in agrochemical industries.

    Management acknowledged

  • Cyclicality of Chemical and Pharmaceutical Industries

    medium

    With the cyclicality that comes with these markets, diversification becomes an important part of our strategy.

    Management acknowledged

  • International Business Slowdown (especially Europe and China)

    medium

    International business will see a little bit of slowdown, continuing longer than expected in India, with headwinds especially in China.

    Management acknowledged

  • Market Recovery Slower Than Expected

    medium

    The market didn't turn as early as management would have liked, with a few more quarters expected before a full turnaround in chemical and pharmaceutical industries.

    Management acknowledged

Q&A highlights

3 direct
India Business Performance and Glass-Lined Equipment (GLE) Recovery Direct
One is flattening of the decline in glass line so we have sort of stabilized and starting to grow both volumes and pricing in glass line, but also the actions we have taken to improve our cost position in our business.

Reveals the underlying drivers of India business improvement, specifically the stabilization and recovery in the core GLE segment, coupled with cost rationalization and diversification efforts.

Asked by Jaiveer Shekhawat

International Business Slowdown and Manufacturing Rationalization Direct
What we are trying to do is rationalize manufacturing to make sure that we take the cost out... One of those initiatives is our Poland strategy... We have also kind of rationalized our UK manufacturing footprint...

Addresses concerns about the international business slowdown, outlining concrete steps (Poland strategy, UK rationalization) taken to improve cost efficiency and adapt to market conditions.

Asked by Jaiveer Shekhawat

Diversification Strategy and Reducing Chemical/Pharma Exposure Direct
our exposure to these segments is reducing, and I would say maybe the next couple of years, it would be down to 50%, because the real growth is going to come from these other industries for two reasons. One, if they are much bigger industry, and two, our market share in those industries is very, very small.

Highlights management's strategic pivot away from heavy reliance on cyclical chemical and pharma sectors, detailing the rationale and target for diversification into new, larger industries with lower current market share.

Asked by Rupesh Tatiya

3 min read 6 chapters

Detailed narrative

Q3 FY25 Financial Performance Overview

GMM Pfaudler reported a stable revenue of approximately INR 801 crores for Q3 FY25. EBITDA saw a 3% increase quarter-on-quarter, with EBITDA margins improving slightly to 12% from 11.6% in the previous quarter. The company's Q3 order intake was strong at INR 798 crore, marking a 5% increase sequentially, and the nine-month order intake was up 13% year-on-year. The order backlog stood at INR 1740 crore, a 7% increase compared to December 31st, 2023.

Market Outlook and Diversification Strategy

Management noted a continued slowdown in the chemical industry, particularly agrochemicals, but observed a slightly more positive outlook than six months prior, expecting some investment return in the next couple of quarters. Recognizing the cyclicality of its core chemical and pharma markets, GMM Pfaudler is actively pursuing diversification. The company aims to reduce its revenue exposure to chemical and pharma segments to 50% over the next couple of years, focusing on new industries like oil & gas, petrochemicals, metals & minerals, wastewater, and semiconductors where market share is currently small but growth potential is high.

Cost Rationalization and Manufacturing Footprint

The company has diligently worked on its cost structure, including rationalizing its manufacturing footprint. In India, all glass-lined production has been consolidated into the Gujarat facility, improving cost absorption and efficiency. The small Hyderabad factory, previously acquired from De-Dietrich, has ceased production, with operations consolidated in Gujarat to optimize fixed costs, though a sales and service presence is maintained in the South market.

International Business and Poland Strategy

The international business experienced a slowdown, particularly in Europe and China, which is expected to continue for a bit longer. To counter this, GMM Pfaudler is rationalizing manufacturing internationally, including moving production from high-cost Western countries to lower-cost European countries like Poland. The company has already executed two successful orders in Poland and plans for a third, with expectations for this strategy to improve efficiencies in Germany and Italy. The UK manufacturing footprint has also been rationalized to improve costs.

India Business Performance and Services Growth

The India business has shown an uptick in revenues and margins after several quarters of decline, driven by the stabilization and recovery of glass-lined volumes and pricing, as well as improved cost positions. Non-glass-lined businesses, especially mixing, heavy engineering, and solid-liquid separation, are also contributing significantly to the improved backlog. Services, currently a single-digit percentage of India revenue, are a priority growth area, aiming to replicate the 35%-40% contribution seen in the international business, with initial results showing promise.

Margin Outlook and Long-Term Vision

EBITDA margins improved to 12% in Q3 FY25, and management expects further improvement in the next financial year, targeting a 15% margin profile across all businesses in the medium term. While the current year is focused on stability and backlog building, the company is working on articulating a long-term strategic vision to the capital markets in the next financial year. This vision will encompass continued diversification, operational efficiency, and leveraging global manufacturing capabilities to deliver consistent quality and timely delivery regardless of manufacturing location.

This is an AI-generated summary of a publicly available earnings call transcript.